Biofluid Research on Age-Related or Inherited Neurodegeneration

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT07798700
Status
Recruiting
Apply to this trial

Conditions

  • ALS (Amyotrophic Lateral Sclerosis)
  • Alzheimer's Disease (AD)
  • Cortical Basal Syndrome (CBS)
  • Dementia With Lewy Bodies (DLB)
  • Familial Frontotemporal Lobar Degeneration (fFTLD)
  • Fronto-temporal Lobar Dementia
  • Frontotemporal Degeneration (FTD)
  • Limbic-predominant Age-related TDP-43 Encephalopathy (LATE)
  • Parkinson's Disease (PD)
  • Parkinson's Disease Dementia (PDD)
  • Posterior Cortical Atrophy (PCA)
  • Primary Lateral Sclerosis (PLS)
  • Primary Muscular Atrophy (PMA)
  • Primary Progressive Aphasia (PPA)
  • Progressive Supranuclear Palsy(PSP)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the molecular and genetic basis of these diseases and their risk factors.

Key Dates

First listed
Sep 1, 2026
Start date
Dec 12, 2025
Status verified
Aug 2026
Primary completion
Jan 1, 2070
Completion
Jan 1, 2070

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: People with a clinical diagnosis of neurodegenerative disease
    People with a clinical diagnosis of a neurodegenerative disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), primary progressive aphasia (PPA), limbic-predominant age-related TDP-43 encephalopathy (LATE), corticobasal syndrome (CBS), posterior cortical atrophy (PCA), primary lateral sclerosis (PLS), primary muscular atrophy (PMA), or individuals with a suspected neurodegenerative dementia and/or movement disorder of unknown etiology will be considered for enrollment.
  • Arm: Family members of individuals meeting criteria for group 1
    Family Members of individuals who meet the criteria of group 1, who are people who may or may not be at risk for a similar neurodegenerative disease, who may or may not be symptomatic, and who may or may not have known or unknown genetic risk.
  • Arm: Healthy Controls
    People with no known neurological disease who will provide control data.

Primary Outcome Measure

To contribute to and continue to sustain a repository biological samples and data from individuals with age-related neurodegenerative conditions. [ Time Frame: This is a natural history study-participants are followed from date of enrollment until death, withdraw, or funding is no longer available, or until 600 months have passed. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104
Cara Joyce, MPH
[email protected]
267-271-0740
Emily Xie
[email protected]
Corey McMillan, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
University of Pennsylvania· Philadelphia, PA

Related Studies